Treat-to-Target Endoscopic Remission in IBD Patients
250
about 5.7 years
18+
22 sites in CA, CO, CT +12
What this study is about
This trial is testing whether switching to a different targeted immunomodulator (TIM) therapy, aiming for endoscopic remission, is more effective than continuing the current TIM in people with inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis, who are currently in symptomatic remission but have moderate to severe inflammation on endoscopy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Pragmatic
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Time to Treatment Failure
Secondary: Overall Quality of Life
Gastroenterology